弥漫性大B细胞淋巴瘤-话题@MedSci

#弥漫性大B细胞淋巴瘤#

54篇内容 | 4040人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1290179, encodeId=7e5512901e9ca, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, objectType=article, longId=295542, objectId=e92329554273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92329554273, replyNumber=0, likeNumber=98, createdTime=2022-02-14, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92329554273, moduleTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92329554273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290178, encodeId=1d4e12901e8f3, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Ann Hematol：弥漫性大b细胞淋巴瘤诊断1年后幸存者的生活质量: 一项LYSA研究, objectType=article, longId=218340, objectId=2dc9218340ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc9218340ef, replyNumber=0, likeNumber=99, createdTime=2021-10-11, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc9218340ef, moduleTitle=Ann Hematol：弥漫性大b细胞淋巴瘤诊断1年后幸存者的生活质量: 一项LYSA研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dc9218340ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290177, encodeId=045612901e746, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标, objectType=article, longId=215050, objectId=6c75215050c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c75215050c9, replyNumber=0, likeNumber=92, createdTime=2021-07-31, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c75215050c9, moduleTitle=iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c75215050c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290176, encodeId=69df12901e600, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle= Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, objectType=article, longId=207556, objectId=3aa220e556bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aa220e556bc, replyNumber=0, likeNumber=130, createdTime=2021-02-26, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aa220e556bc, moduleTitle= Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aa220e556bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290175, encodeId=1f8c12901e5e2, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, objectType=article, longId=207011, objectId=dcad20e01104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcad20e01104, replyNumber=0, likeNumber=89, createdTime=2021-02-11, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcad20e01104, moduleTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcad20e01104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290174, encodeId=731812901e4eb, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, objectType=article, longId=205595, objectId=b9f020559582, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9f020559582, replyNumber=0, likeNumber=90, createdTime=2021-01-12, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9f020559582, moduleTitle=Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9f020559582)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290173, encodeId=7db812901e386, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果, objectType=article, longId=204967, objectId=9ede20496e6a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ede20496e6a, replyNumber=0, likeNumber=94, createdTime=2020-12-30, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ede20496e6a, moduleTitle=Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ede20496e6a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290172, encodeId=cd9212901e2a6, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, objectType=article, longId=198654, objectId=e12d1986548a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12d1986548a, replyNumber=0, likeNumber=72, createdTime=2020-08-05, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12d1986548a, moduleTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12d1986548a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290171, encodeId=882b12901e193, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, objectType=article, longId=197011, objectId=7c6419e01122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c6419e01122, replyNumber=0, likeNumber=73, createdTime=2020-07-05, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c6419e01122, moduleTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c6419e01122)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290170, encodeId=c92112901e021, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, objectType=article, longId=195473, objectId=16a61954e3e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16a61954e3e1, replyNumber=0, likeNumber=85, createdTime=2020-06-09, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16a61954e3e1, moduleTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16a61954e3e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290169, encodeId=ea651290169be, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, objectType=article, longId=193101, objectId=1e4d193101ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4d193101ba, replyNumber=0, likeNumber=129, createdTime=2020-04-30, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4d193101ba, moduleTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4d193101ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, objectType=article, longId=188486, objectId=9acb18848624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb18848624, replyNumber=0, likeNumber=73, createdTime=2020-02-22, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb18848624, moduleTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9acb18848624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290167, encodeId=a9b3129016e1b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, objectType=article, longId=187714, objectId=782818e714bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782818e714bf, replyNumber=0, likeNumber=108, createdTime=2020-02-10, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782818e714bf, moduleTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782818e714bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290166, encodeId=2a861290166e8, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, objectType=article, longId=187601, objectId=3fc418e60132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fc418e60132, replyNumber=0, likeNumber=73, createdTime=2020-02-08, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc418e60132, moduleTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc418e60132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290165, encodeId=7231129016563, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=0, createdTime=2020-01-11, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, objectType=article, longId=183346, objectId=525e183346c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525e183346c6, replyNumber=0, likeNumber=84, createdTime=2019-11-23, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525e183346c6, moduleTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525e183346c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290163, encodeId=37ad12901632b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=J Gastroenterology：PD-L1表达在原发性胃和肠弥漫性大B细胞淋巴瘤中的预后影响, objectType=article, longId=179701, objectId=85981e970172, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85981e970172, replyNumber=0, likeNumber=65, createdTime=2019-09-20, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85981e970172, moduleTitle=J Gastroenterology：PD-L1表达在原发性胃和肠弥漫性大B细胞淋巴瘤中的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85981e970172)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290162, encodeId=fc931290162a5, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Blood：弥漫性大B细胞淋巴瘤CD37基因免疫优势位点的高发突变, objectType=article, longId=176755, objectId=ddc71e6755b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddc71e6755b1, replyNumber=0, likeNumber=81, createdTime=2019-08-04, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddc71e6755b1, moduleTitle=Blood：弥漫性大B细胞淋巴瘤CD37基因免疫优势位点的高发突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddc71e6755b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290161, encodeId=fd0812901618b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用, objectType=article, longId=168705, objectId=eb1e168e0594, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb1e168e0594, replyNumber=0, likeNumber=94, createdTime=2019-06-20, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb1e168e0594, moduleTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb1e168e0594)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1290160, encodeId=8d4e12901609a, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用继续闪耀, objectType=article, longId=168636, objectId=b21a168636d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b21a168636d1, replyNumber=0, likeNumber=59, createdTime=2019-06-19, rootId=0, userName=bnjfy, userId=346311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b21a168636d1, moduleTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用继续闪耀, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b21a168636d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

弥漫性大B细胞淋巴瘤

2020-05-29

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤

2022-02-14

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Ann Hematol：弥漫性大b细胞淋巴瘤诊断1年后幸存者的生活质量: 一项LYSA研究

2021-10-11

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标

2021-07-31

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关

2021-02-26

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期

2021-02-11

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关

2021-01-12

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果

2020-12-30

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤

2020-08-05

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤

2020-07-05

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效

2020-06-09

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率

2020-04-30

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤

2020-02-22

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤

2020-02-10

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响

2020-02-08

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-01-11

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定

2019-11-23

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

J Gastroenterology：PD-L1表达在原发性胃和肠弥漫性大B细胞淋巴瘤中的预后影响

2019-09-20

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

Blood：弥漫性大B细胞淋巴瘤CD37基因免疫优势位点的高发突变

2019-08-04

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

来那度胺在弥漫性大B细胞淋巴瘤中的应用

2019-06-20

bnjfy (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤#

来那度胺在弥漫性大B细胞淋巴瘤中的应用继续闪耀

2019-06-19

科室
- - 订阅+
  - 更多科室
工具
服务